A novel chimaeric derivative of saruplase, rscu-PA-40kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs

Thrombosis and Haemostasis

Volumn 77, Issue 3, 1997, Pages 535-539

  Schneider, J ^a   Hauser, R ^a   Hennies, H H ^a   Korioth, J ^a   Steffens, G ^a   Wnendt, S ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT; HIRUDIN; IODINE 125; M 23; PROTEINASE; SARUPLASE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CHIMERA; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRUCTURE ACTIVITY RELATION; VEIN THROMBOSIS;

EID: 0030979959     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656002     Document Type: Article

References (18)

1. Reiner JS, Wasserman AG. The role of thrombolytic therapy for acute myocardial infarction. Cor Art Dis 1994; 5: 373-9.
2. Simes RJ, Topol EJ, Holmes, DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995; 91: 1923-8.
3. Shammas NW, Zeitler R, Fitzpatrick P. Intravenous thrombolytic therapy in myocardial infarction: an analytical review. Clin Cardiol 1993; 16: 283-92.
4. Verstraete M. Advances in thrombolytic therapy. Cardiovasc Drugs Ther 1992; 6: 111-24.
5. Francis CW, Markham RE, Barlow GH, Florack ThM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
6. Phaneuf MD, Ozaki CK, Johnstone MT, Loza JP, Quist, WC, LoGerfo FW. Covalent linkage of streptokinase to recombinant hirudin: a novel thrombolytic agent with antithrombotic properties. Thromb Haemostas 1994; 71: 481-7.
7. Wnendt S, Janocha E, Schneider J, Steffens GJ. Construction and structure/function relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential. Protein Engineering 1996; 9: 213-23.
8. Hanbücken FW, Schneider J, Günzler WA, Friderichs E, Giertz H, Flohé L. Selective fibrinolytic activity of recombinant non-glycosylated human prourokinase (single chain urokinase-type plasminogen activator) from bacteria. Arznm Forsch/Drug Res 1987; 37: 993-7.
9. Lijnen HR, Wnendt S, Schneider J, Janocha E, van Hoef B, Collen D, Steffens GJ. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. Eur J Biochem 1995; 234: 350-7.
10. Schneider J, Wnendt S, Saunders D, Heinzel-Wieland R, Wilffert B, Steffens G. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDA/Hir). Eur J Pharmacol 1996; 302: 69-77.
11. 125I-containing acylating agent. Biochem J 1973; 133: 529-39.
12. Clauss A. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 1957; 17: 237-46.
13. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-36.
14. Seitz R, Blanke H, Prätorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemostas 1988; 59: 541-2.
15. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Raffenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991; 83: 937-44.
16. PRIMI-trial study group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. The Lancet 1989; April 22, 8643: 863-8.
17. Rapold HJ, Wu Z, Stassen T, van de Werf F, Collen D. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis. Blood 1990; 76: 1558-63.
18. Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis. Thromb Res 1988; 51: 63-74.